Form 4: Spyre Therapeutics Director Sandra Milligan Granted 25,000 Stock Options

Spyre Therapeutics, Inc. Director Sandra Milligan was granted 25,000 stock options with an exercise price of $15.55, vesting over 12 months.

Summary

• Sandra Milligan, a Director of Spyre Therapeutics, Inc. (SYRE), was granted 25,000 stock options.
• The options have an exercise price of $15.55 per share.
• The transaction date for this grant was May 29, 2025.
• These options will vest and become exercisable in 12 equal monthly installments following May 29, 2025.
• Full vesting is contingent upon Ms. Milligan's continuous service with the Issuer at each vesting date.
• The options have an expiration date of May 29, 2035.
• Following this transaction, Ms. Milligan directly beneficially owns 25,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it represents a routine compensation event that aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages the director's continued service and commitment to the company over the next year.

Future Outlook

The grant of stock options with a vesting schedule over the next 12 months indicates an expectation of continued service from the director and aims to incentivize long-term value creation.

Management Comments

• The grant of stock options to Director Sandra Milligan reflects a standard compensation practice aimed at aligning management and director incentives with shareholder interests.

Industry Context

This Form 4 filing details a routine equity compensation event for a director in a publicly traded biotechnology company. Granting stock options is a common practice across industries, particularly in biotech, to attract and retain talent, and to align the interests of directors and executives with the long-term performance of the company.

Corporate Governance

Related Party Transactions

• The grant of 25,000 stock options to Sandra Milligan, a Director of Spyre Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The option grant aims to align the director's interests with shareholders by tying compensation to stock performance, potentially leading to increased long-term value.
• Employees: While not directly impacting all employees, such compensation practices can set a precedent for executive and director incentives within the company.

Next Steps

• The granted stock options will vest in 12 equal monthly installments following May 29, 2025, subject to continuous service.

Key Dates

Keywords

Spyre Therapeutics, SYRE, Stock Option, Insider Transaction, Director Compensation, Form 4, Beneficial Ownership, Equity Grant